柳藥集團(603368.SH)2022年度淨利潤預增22.79%
格隆匯2月8日丨柳藥集團(603368.SH)公佈,公司預計2022年度實現營業收入約190.92億元,同比增長約11.42%;預計2022年度實現歸屬於上市公司股東的淨利潤約6.92億元,同比增長約22.79%;預計2022年度實現歸屬於上市公司股東的扣除非經常性損益的淨利潤約6.86億元,同比增長約24%。
2022年公司經營業績保持穩健增長,主要原因是:公司緊密圍繞既定的發展戰略紮實開展工作,落實傳統業態轉型升級、工業板塊做大做強戰略。在批發板塊,公司搶抓優質品種,強化品種優勢,持續開展藥械耗材SPD項目,穩步提升批發市場規模,尤其加快器械耗材市場份額的提升。在零售板塊,公司強化批發與零售協同,推動處方外延、慢病管理、DTP等專業創新業務發展,保持零售業務業績穩健增長。在工業板塊,公司逐步提升工業產能規模,根據市場需求豐富產品品種,發揮公司批發和零售渠道優勢,加快自產品種的市場拓展,工業板塊對公司的利潤貢獻持續擴大,已發展成為公司新的利潤增長點。此外,公司中藥配方顆粒項目已完成近400個品種備案工作,同時公司已逐步開展核心醫院市場的配方顆粒產品進院工作,為未來實現業績放量奠定基礎。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.